Quarterly report pursuant to Section 13 or 15(d)

Loans Receivable

v3.24.1.1.u2
Loans Receivable
3 Months Ended
Mar. 31, 2024
Loans Receivable  
Loans Receivable

8. Loans Receivable

A breakdown of the loans receivable terms and balances are as follows:

Loans receivable

    

March 31, 2024

    

December 31, 2023

Teneo Fund SPVi LLC Note

$

5,586

$

5,622

Pharma EU, LLC Note

1,410

1,410

A&R Note

710

710

SSZ and Elev8 Note

1,002

1,002

Pure Hana Synergy Note

224

224

Little Beach Harvest Note

Total loans receivable

$

8,932

$

8,968

Less allowance for expected credit losses

(7,902)

(7,902)

Loans receivable

$

1,030

$

1,066

Little Beach Harvest Note

In June 2023, the Company determined that it may not be able to collect the full amount of its loan receivable from Little Beach Harvest (the “Little Beach Harvest Note”). As a result, the Company did not record any interest income for the three months ended March 31, 2024.

On September 1, 2023, due to a strategic shift to focus on the Company’s core business, the Company divested its interests in its joint venture in Standard Farms New York LLC (“SFNY”) pursuant to a membership interest purchase agreement (“MIPA”) by and among SFNY Holdings Inc. (“SFNY Holdings”), SFNY, each wholly owned subsidiaries of the Company, and CGSF Investments, LLC (“CGSF”), a wholly owned subsidiary of PowerFund Holdings II LLC (the “CGSF/SFNY Divestiture”). As a result, the Company wrote off the principal of the Little Beach Harvest Note as well as related accrued interest totaling $5,135 and the balance no longer exists.

The Little Beach Harvest Note loan receivable balance was subject to an interest rate of 9.0%. Interest income was $64 for the three months ended March 31, 2023 and is included in interest income on the condensed consolidated statements of income and comprehensive loss.

Impairment

At each reporting date, the Company assesses whether loans receivables are credit impaired by applying the guidance in ASC 326. A financial asset is considered “credit impaired” when one or more events that have a detrimental impact on the estimated future cash flows of the financial asset have occurred. Credit impairment is based on observable data such as significant financial difficulty of the debtor and a breach of contract such as a default or being past due. During the three months ended March 31, 2024, the Company did not record additional allowance for expected credit losses related to its remaining loans receivable.

Current expected credit loss (“CECL”) reserves are measured by the Company on a probability-weighted basis based on historical experience, current conditions, and reasonable and supportable forecasts. Our assessment includes a variety of factors, including underlying credit, relative maturity dates of the loans, economic considerations, as well as ongoing legal and other regulatory developments in the industry. The process includes consideration for the assumed recovery rate from underlying collateral, with adjustments for time value of money and estimated costs for obtaining and selling the collateral. Given the repayment profile and underlying terms of such loans, CECL reserves are generally estimated over the contractual term of the loan.

The following tables present an analysis of the credit quality of loans receivable, together with impairment losses recognized based on lifetime CECL reserves:

As of March 31, 2024

Nature of collateral

    

Gross amounts

    

Loan losses

    

Net

Security interest in assets of counterparty

$

7,298

$

(6,268)

$

1,030

Third party guarantee

1,410

(1,410)

No collateral

224

(224)

Net loans receivable

$

8,932

$

(7,902)

$

1,030

As of December 31, 2023

Nature of collateral

    

Gross amounts

    

Loan losses

    

Net

Security interest in assets of counterparty

$

7,334

$

(6,268)

$

1,066

Third party guarantee

1,410

(1,410)

No collateral

224

(224)

Net loans receivable

$

8,968

$

(7,902)

$

1,066